We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Olufikayo
Bamidele
Olufikayo.Bamidele@hyms.ac.uk
Olufikayo
Bamidele
Olufikayo.Bamidele@hyms.ac.uk
Olufikayo
Bamidele
O.Bamidele@hull.ac.uk
Malignant neoplasms of male genital organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Prostate cancer (CaP) disproportionately affects 1 in 4 Black men compared with 1 in 8 White and 1 in 13 Asian men. Early diagnosis enhances men’s survival from CaP. However, evidence suggests that self, public and structural stigma prevent men of Black African and Caribbean descent from talking openly about CaP and from seeking timely help for symptoms probably due to its association with death and/or lessened masculinity. This causes delays in diagnosis and increased death rates from CaP. However, it is unclear how best to tackle this stigma within the Black cultural context due to a lack of research. Therefore our study aims to understand the perceptions or experiences of stigma related to CaP within Black communities.
Between March 2025 and February 2030, we will work in partnership with Black men and their communities in the UK to conduct the research in four phases:
1.Phase one: interviews and/or focus groups, and surveys with adult Black men diagnosed with CaP, Black men without CaP aged 40 years and above, and partners/immediate families of Black men with CaP (those who may influence men’s decision-making) to understand their experiences/perceptions of stigma. Clinicians involved in CaP diagnosis and care will also be interviewed to explore their perceptions of the topic.
2.Phase two: Evidence synthesis and stakeholder engagement workshops with Black men and their communities to discuss findings from phase one and co-produce culturally appropriate educational and/or information resources to inform public health messaging on CaP
3.Phase three: Focus groups and/or interviews with Black men and their families to assess the acceptability of resources co-produced in phase two. Comments received will be used to improve the resources for use in clinical and community settings
4.Phase four: Test the feasibility (practicability) of incorporating the resources in clinical/community settings to improve patient care and early engagement with cancer services.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
Group 1 Black men with prostate cancer on end of life care as their needs and experiences will be beyond the scope of the current study; Black men with prostate cancer who are too ill to participate (as indicated by men themselves, HCP or family member) Group 2 Black men resident outside the study setting of England Group 3 Partners and/or family members resident outside of England (as the context of their views and experiences may be outside the scope of this study) Partners and/or family members of Black men who have not yet experienced a prostate cancer diagnosis Group 4 HCPs in primary or secondary care without direct access to men with prostate cancer nor influence on clinical decision-making regarding CaP diagnosis and/or care
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Olufikayo
Bamidele
Olufikayo.Bamidele@hyms.ac.uk
Olufikayo
Bamidele
Olufikayo.Bamidele@hyms.ac.uk
Olufikayo
Bamidele
O.Bamidele@hull.ac.uk
The study is sponsored by University of Hull and funded by NIHR Academy .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 60146
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
